J84.10 Insurance Policy Changes

ICD-10 J84.10 is officially defined as "Pulmonary fibrosis, unspecified." code J84.10 is referenced in 5 tracked payer policy changes from Aetna and Blue Cross & Blue Shield of Mississippi. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code J84.10 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Oct 6, 2026Medium impact
Lung Transplantation (CPB 0598, reviewed 2026-09-08)
Aetna considers lung transplantation medically necessary for qualifying conditions including cystic fibrosis, emphysema and alpha-1-antitrypsin deficiency, Eisenmenger's complex, primary pulmonary hypertension, pulmonary fibrosis, sarcoidosis, lymphangioleiomyomatosis with end-stage pulmonary disease, bronchopulmonary dysplasia, and graft-versus-host disease or failed primary lung graft, when the member meets the transplanting institution's selection criteria or, without those criteria, the general and disease-specific criteria in the policy. Cystic fibrosis requires at least 2 listed signs of clinical deterioration, such as decreasing FEV1, FEV1 less than 30% predicted, or recurrent massive hemoptysis, and emphysema requires both hospitalization for COPD exacerbation with hypercapnia in the preceding year and a BODE index of 7 or above. Lung transplantation is considered not medically necessary for malignancy involving the lung, multi-system disease, refractory uncontrolled hypertension, other effective treatments being available, and smoking without 6 months of abstinence.
Aetna · Identified Oct 4, 2026Medium impact
Heart-Lung Transplantation (CPB 0597, reviewed 2026-09-08)
Aetna considers heart-lung transplantation medically necessary for persons with severe refractory heart failure plus either end-stage lung disease or irreversible pulmonary hypertension, when the selection criteria are met and no absolute contraindications are present. Examples of qualifying conditions include COPD with severe heart failure, cystic fibrosis with severe heart failure, congenital heart disease with pulmonary hypertension that is not amenable to lung transplantation and repair by standard cardiac surgery, and Eisenmenger's complex with irreversible pulmonary hypertension and severe heart failure. Heart-lung transplantation is considered not medically necessary where lung transplantation alone will restore right ventricular function.
Aetna · Identified Aug 18, 2026Medium impact
Lung Imaging: Selected Techniques (CPB 0581, reviewed 2026-02-24)
Aetna considers lung imaging fluorescence endoscopy (LIFE) medically necessary to enhance the physician's ability to detect and biopsy abnormal bronchial tissue suspicious for pre-cancerous lesions, carcinomas in situ, and early bronchogenic carcinomas in members with known or previously diagnosed lung cancer, members with suspected lung cancer, and members with a previously resected Stage I lung cancer who have no evidence of metastatic disease and are at risk for secondary disease. Suspected lung cancer includes positive sputum cytology, hemoptysis, infiltrates, or pneumonia signs or symptoms that do not resolve within 30 days of treatment, persistent cough, or a positive X-ray. Aetna considers computer-aided lung informatics for pathology evaluation and rating (CALIPER) for interstitial lung disease, contrast-enhanced ultrasonography for diagnosis of lung cancer, LIFE for all other indications, 3D lung CT for evaluation of bronchial anatomy, point laser Raman spectroscopy, XV LVAS pulmonary tissue ventilation analysis, and Xenon Xe-129 hyperpolarized gas (Xenoview) for lung ventilation evaluation experimental, investigational, or unproven. The CPT codes 0807T, 0808T, 0877T, 0878T, 0879T, 0880T, 76376, 76377, 76978, and 76979 and the HCPCS codes A9610 and C9791 are listed as not covered for the indications in this policy. source issue date 2026-02-24.
Aetna · Identified Aug 17, 2026Medium impact
Heart-Lung Transplantation (CPB 0597, reviewed 2025-12-02)
Aetna considers heart-lung transplantation medically necessary for persons with severe refractory heart failure plus either end-stage lung disease or irreversible pulmonary hypertension, when the selection criteria are met and no absolute contraindications are present. Heart-lung transplantation is considered not medically necessary where lung transplantation alone will restore right ventricular function, and every attempt should be made to preserve the heart. The member must meet the transplanting institution's selection criteria, and in the absence of those criteria, Aetna's listed criteria apply.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Heart/Lung Transplant
Heart/lung transplantation is considered medically necessary for carefully selected individuals with end-stage cardiac and pulmonary disease, including irreversible primary pulmonary hypertension with heart failure, cystic fibrosis with severe heart failure, emphysema with severe heart failure, and pulmonary fibrosis with uncontrollable pulmonary hypertension or heart failure. Heart/lung retransplantation after a failed primary heart/lung transplant may be considered medically necessary for individuals who meet the criteria for heart/lung transplantation. Heart/lung transplantation in all other situations is considered investigational.

Watch J84.10

Get one email when a payer policy names J84.10, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code J84.10?

There are 5 tracked policy changes affecting code J84.10, including updates from Aetna, Blue Cross & Blue Shield of Mississippi. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code J84.10?

Payers that have issued tracked updates for code J84.10 include: Aetna, Blue Cross & Blue Shield of Mississippi.

How do I get notified when code J84.10 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code J84.10. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code J84.10?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Lung Transplantation (CPB 0598, reviewed 2026-09-08)

Heart-Lung Transplantation (CPB 0597, reviewed 2026-09-08)

Lung Imaging: Selected Techniques (CPB 0581, reviewed 2026-02-24)

Heart-Lung Transplantation (CPB 0597, reviewed 2025-12-02)

Heart/Lung Transplant

What insurance policy changes affect code J84.10?

Which payers have updated policy for code J84.10?

How do I get notified when code J84.10 policy changes?

Why do payers change policies for code J84.10?